SRRK - Scholar Rock Holding Corporation
| Previous Close | 10.74 |
| Open | 10.44 |
| Bid | 10.14 x 1000 |
| Ask | 11.00 x 800 |
| Day's Range | 10.13 - 10.93 |
| 52 Week Range | 6.95 - 23.35 |
| Volume | 33,995 |
| Avg. Volume | 115,188 |
| Market Cap | 302.126M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.06 |
| Earnings Date | Mar 15, 2020 - Mar 19, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.00 |
- GlobeNewswire
Scholar Rock Provides Corporate Update and Outlines Key R&D Priorities for 2020
Scholar Rock (SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today highlighted key accomplishments of the past year and announced R&D priorities for 2020. SRK-015: highly specific inhibitor of latent myostatin activation being developed for the treatment of Spinal Muscular Atrophy (SMA).
- GlobeNewswire
Scholar Rock Achieves First Milestone in Strategic Fibrosis Collaboration with Gilead Sciences
Scholar Rock (SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the Company has earned a $25 million milestone payment from Gilead Sciences, Inc. (GILD) for the successful demonstration of efficacy in preclinical in vivo proof-of-concept studies. This is the most advanced program of the collaboration focused on the discovery and development of potent and selective inhibitors of latent transforming growth factor beta (TGFβ) activation for the treatment of fibrotic diseases. “Achieving this important first milestone at the one year mark of the collaboration is indicative of the progress we are making together towards unlocking the potential of this novel approach to TGFβ inhibition in the treatment of patients suffering from fibrotic diseases,” said Nagesh Mahanthappa, Ph.D., President and CEO of Scholar Rock.
- GlobeNewswire
Scholar Rock Added to NASDAQ Biotechnology Index
Scholar Rock Holding Corporation (SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq:NBI), effective prior to market open on Monday, December 23, 2019. The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities that are classified as either Biotechnology or Pharmaceutical according to the Industry Classification Benchmark (ICB). The Index is evaluated annually and serves as the basis for the iShares NASDAQ Biotechnology Index Fund (IBB).
- Insider Monkey
Here is What Hedge Funds Think About Scholar Rock Holding Corporation (SRRK)
Hedge funds are known to underperform the bull markets but that's not because they are terrible at stock picking. Hedge funds underperform because their net exposure in only 40-70% and they charge exorbitant fees. No one knows what the future holds and how market participants will react to the bountiful news that floods in each […]
- GlobeNewswire
Scholar Rock Reports Preliminary Pharmacokinetic and Pharmacodynamic Data from TOPAZ Phase 2 Trial of SRK-015 for the Treatment of Patients with Spinal Muscular Atrophy
Scholar Rock (SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced preliminary pharmacokinetic (PK) and pharmacodynamic (PD) results from the TOPAZ Phase 2 proof-of-concept trial of SRK-015 for the treatment of patients with spinal muscular atrophy (SMA). The planned preliminary PK/PD analysis, which includes data from 29 patients with SMA across all three cohorts, showed dose-proportional drug exposure and demonstrated target engagement, as evidenced by dose-dependent increases of up to 100-fold in the serum levels of latent myostatin following SRK-015 treatment (2 mg/kg and 20 mg/kg doses).
- Zacks
Scholar Rock Holding Corporation (SRRK) Reports Q3 Loss, Misses Revenue Estimates
Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -77.42% and -62.48%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Scholar Rock Reports Third Quarter 2019 Financial Results and Highlights Business Progress
Enrollment on track in the TOPAZ Phase 2 clinical trial of SRK-015 in patients with Type 2 and Type 3 Spinal Muscular Atrophy for preliminary PK/PD results by.
- GuruFocus.com
Analysts See 2 Falling Knives Bouncing Back
They have a low financial burden Continue reading...
- GlobeNewswire
Scholar Rock to Present at the 2019 Jefferies London Healthcare Conference
CAMBRIDGE, Mass., Nov. 08, 2019 -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in.
- Insider Monkey
Hedge Funds Have Never Been This Bullish On Scholar Rock Holding Corporation (SRRK)
Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 due to various reasons. Nevertheless, the data show elite investors' consensus picks have done well on average over the long-term. The top 20 stocks among hedge funds beat the S&P […]
- GlobeNewswire
Scholar Rock to Present Preclinical and Phase 1 Clinical Data on SRK-015 at the World Muscle Society Congress
Scholar Rock (SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that a poster presentation of preclinical and Phase 1 healthy volunteer data for SRK-015 will be presented at the World Muscle Society Congress being held October 1-5, 2019 in Copenhagen, Denmark. SRK-015 is a highly selective inhibitor of the activation of myostatin, a negative regulator of muscle mass, and is being evaluated in the TOPAZ Phase 2 clinical trial for the treatment of patients with Type 2 and Type 3 spinal muscular atrophy (SMA).
- Zacks
Will Scholar Rock Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor Scholar Rock Holding.
- GlobeNewswire
Scholar Rock to Present at Upcoming Healthcare Conferences
CAMBRIDGE, Mass., Sept. 04, 2019 -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in.
- Simply Wall St.
Is There An Opportunity With Scholar Rock Holding Corporation's (NASDAQ:SRRK) 21% Undervaluation?
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Scholar Rock Holding...
- GlobeNewswire
Scholar Rock Announces Upcoming Departure of Chief Financial Officer
Scholar Rock Holding Corporation (SRRK), a clinical stage biopharmaceutical company, announced today that its Chief Financial Officer, Rhonda Chicko, will be leaving the Company to pursue other opportunities. The Company has initiated a search for a new Chief Financial Officer. “Scholar Rock’s Board of Directors, management team, and employees are sincerely grateful to Rhonda for her many contributions to the company and we wish her well in her future endeavors,” said Nagesh Mahanthappa, Ph.D., President and CEO of Scholar Rock.
- GlobeNewswire
Scholar Rock Reports Second Quarter 2019 Financial Results and Highlights Business Progress
Enrollment on track in the TOPAZ Phase 2 clinical trial of SRK-015 in patients with Type 2 and Type 3 Spinal Muscular Atrophy for preliminary PK/PD results by year-endPresented.
- GlobeNewswire
Scholar Rock to Present at the 2019 Wedbush PacGrow Healthcare Conference
CAMBRIDGE, Mass., Aug. 07, 2019 -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in.
- Simply Wall St.
Did Changing Sentiment Drive Scholar Rock Holding's (NASDAQ:SRRK) Share Price Down By 19%?
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. Active...
- Motley Fool
Why Carnival, Steelcase, and Scholar Rock Holding Slumped Today
Find out why these stocks missed the rally.
- Motley Fool
Why Scholar Rock Is Sinking Today
The good news? The cause of the drop should be a temporary issue.
- GlobeNewswire
Scholar Rock Announces Pricing of Public Offering of Common Stock
Scholar Rock Holding Corporation (SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the pricing of an underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $15.00 per share. The gross proceeds to Scholar Rock from this offering are expected to be $45 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, Scholar Rock has granted the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock.
- GlobeNewswire
Scholar Rock to Present at the 2019 BMO Prescriptions for Success Healthcare Conference
CAMBRIDGE, Mass., June 19, 2019 -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in.
- GlobeNewswire
Scholar Rock Announces Proposed Public Offering of Common Stock
Scholar Rock Holding Corporation (SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that it intends to offer and sell in an underwritten public offering 3,000,000 shares of its common stock. In addition, Scholar Rock has granted the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock. All of the shares are being offered by Scholar Rock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Scholar Rock intends to use the net proceeds from the offering to fund the SRK-015 program for the treatment of Spinal Muscular Atrophy (SMA), the SRK-181 program for the treatment of cancers that are resistant to checkpoint blockade therapies, preclinical activities for other pipeline programs, as well as for working capital and other general corporate purposes.
- GlobeNewswire
Scholar Rock Announces Positive Final Results from Phase 1 Clinical Trial of SRK-015 in Healthy Volunteers
“We are pleased to be presenting the Phase 1 SRK-015 trial results at the upcoming Cure SMA annual conference as these data provide initial safety and mechanistic insights for SRK-015 and support our Phase 2 program,” said Yung Chyung, M.D., Chief Medical Officer of Scholar Rock. “The pharmacodynamic results from the Phase 1 trial offer initial proof-of-mechanism for Scholar Rock’s unique therapeutic approach of targeting the latent form of growth factors,” said Nagesh Mahanthappa, Ph.D., President and CEO of Scholar Rock.
- GlobeNewswire
Scholar Rock to Present at the Jefferies 2019 Global Healthcare Conference
CAMBRIDGE, Mass., May 28, 2019 -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in.
